Tomasz Tafliński

Institute of Psychiatry and Neurology, Warszawa, Masovian Voivodeship, Poland

Are you Tomasz Tafliński?

Claim your profile

Publications (4)6.42 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic disturbances are a growing concern for the treatment of schizophrenia. As decreased activity and poor sleep quality are risk factors for metabolic disturbances, we investigated the activity and sleep patterns of schizophrenic patients using actigraphy. Seventy-three patients with schizophrenia spectrum disorder (mean age 29.2 ± 10.2 years, 27 females) treated with olanzapine (n = 54) or risperidone (n = 19) and 36 age- and sex-matched healthy controls were examined. Actigraphic recordings were obtained throughout seven consecutive days. The Athens Insomnia Scale (AIS) and Epworth Sleepiness Scale (ESS) were used to assess sleep and daytime sleepiness. Drug side effects were evaluated with the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale and Barnes Akathisia Rating Scale (BARS). Mental status was rated with the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS). The patients had lower mean 24 h-activity (p < 0.001) and mean 10 h-daytime-activity (p < 0.001), and longer time in bed (p < 0.001). Higher PANSS scores, especially in the negative symptoms scale, were related to lower activity (r(s) = -0.508, p < 0.001). Higher depressive symptoms were related to lower mean 24 h-activity (r(s) = -0.233, p = 0.049), longer time in bed (r(s) = 0.315, p = 0.007) and higher AIS (r(s) = 0.377, p = 0.001) and ESS scores (r(s) = 0.321, p = 0.006). Healthy females presented higher activity than healthy males (p < 0.001). Similar but not significant gender differences were observed in the patients. These findings show that patients with schizophrenia treated with olanzapine or risperidone exhibit low physical activity and altered sleep pattern which may promote metabolic side effects. These changes are linked to negative and depressive symptoms.
    Journal of Psychiatric Research 06/2011; 45(10):1381-6. DOI:10.1016/j.jpsychires.2011.05.009 · 3.96 Impact Factor
  • Tafliński T. · Jarema M. · Murawiec S ·

    XXIV CINP Congress, Paris, June 20-24,2004; 06/2004
  • Source
    Marek Jarema · Sławomir Murawiec · Tomasz Tafliński ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The study was to evaluate objectively (by a physician) and subjectively (by the patients) the efficacy of 12-months olanzapine treatment of schizophrenic out-patients. Olanzapine treatment was either initiated or patients were switched from other antipsychotics to olanzapine. Patients' subjective evaluation with the use of SWN and DAI scales was compared with physicians' objective evaluation with the use of PANSS, CDS and CGI scales. The treatment with olanzapine caused significant improvement of schizophrenia positive, negative and affective symptoms. The use of the DAI questionnaire revealed also subjective improvement after olanzapine treatment. The decrease of schizophrenic symptoms correlated with the improvement of patients' subjective feeling of self-control, psychic functioning and somatic health. No serious adverse events were seen during the treatment. The severity of adverse events decreased during the olanzapine treatment. Olanzapine treatment of patients suffering from schizophrenia proved to be efficacious in both objective and subjective evaluation.
    Psychiatria polska 01/2004; 38(5):895-909. · 0.73 Impact Factor
  • Source
    S Murawiec · D Taflińska · T Tafliński ·

    Harvard Review of Psychiatry 11/1999; 7(4):241-2. DOI:10.1093/hrp/7.4.241 · 1.73 Impact Factor